

# Gynecologic and Peritoneal Oncology

## Group leader


Céspedes Navarro, María Virtudes (IR)

## Researchers

- Caruana Santiago, Pablo (IR)
- Edwards, Maria Charlotte (IR)
- Farrés Rubí, Alba (FGS)
- Luna Guibourg, Rocío (FGS)
- Magret Descamps, Eva (FGS)
- Martín Lorente, Cristina (FGS)
- Muñoz Sánchez, Raquel (FGS)
- Rovira Negre, Ramón (FGS)
- Soler Moreno, Cristina (FGS)
- Teixera, Natalia (FGS)

## Research technicians

Zapater Enrique, Oscar (FGS)



## DESCRIPTION

The Gynecologic and Peritoneal Oncology research group (GOGYP), coordinated by Dr. Maria Virtudes Céspedes, is an emerging group, led by an established scientist from the Miguel Servet Programme. GOGYP is a clinic-translational research team that belongs to the onco-haematological diseases research area at the Institut de Recerca Sant Pau (IR-HSCSP). They are actively engaged in advancing surgical techniques, developing diagnostic tools, and creating innovative therapies based on nanotechnology. Their research encompasses patient and sample screening, as well as in vitro and in vivo modelling and experimentation. The team also possesses strong expertise in the preclinical development of drugs and clinical assays. The results of their multidisciplinary efforts contribute to three transversal research programs in IR-HSCSP: Advanced Therapies, Prognostic and Diagnostic Biomarkers, and Women's Health and Care.

## MAIN LINES OF RESEARCH

- Identify new prognostic biomarkers and new therapeutic targets for risk and therapeutic stratification in endometrial cancer patients. (Céspedes Navarro, Maria Virtudes).
- Study the effect of the Nervous system in tumor progression and metastasis in gynecological and peritoneal cancers. (Céspedes Navarro, Maria Virtudes).
- Modeling gynecological and peritoneal cancers in animals to better understand tumor

pathophysiology and the use for preclinical drug evaluation. (Céspedes Navarro, Maria Virtudes).

- Evaluation and preclinical development of new antitumor compounds, using nanotechnology, aimed at the treatment of metastases in high-grade gynecological cancers. (Céspedes Navarro, Maria Virtudes).

## SCIENTIFIC CHALLENGES

- Promote clinical and translational research into gynaecological cancers with a huge database and study relevant clinical issues.
- Obtain funding from FIS, regional authorities and private companies.
- Enhance cooperation with other clinical and research groups both within Sant Pau and outside the hospital, and attract predoctoral and postdoctoral fellows.
- Develop molecular markers for informed therapeutic decision-making in patients with endometrial cancer.
- Identification and validation of novel therapeutic targets related to neuromodulation in the tumour progression of gynaecological cancers.
- Achieve antitumor and antimetastatic effects by targeting drugs at cancer stem cells in gynaecological and peritoneal cancers.

## ACTIVE & AWARDED GRANTS

- Caruana Santiago, Pablo. Contractes predoctorals PFIS 2021. FI21/00146. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2025. 119.567,00 €
- Céspedes Navarro, Maria Virtudes. Innovative nanotherapy for highly-metastatic peritoneal cancers: activating neuroreceptors to kill cancer stem cells. PI20/00623. Instituto de Salud Carlos III (ISCIII). Duration: 2021-2024. 173.030,00 €
- Céspedes Navarro, Maria Virtudes. GRUP D'ONCOLOGIA GINECOLOGICA I PERITONEAL (GOGyP). 2022 INV-1 00048.

Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Duration: 2022-2024. 66.217,84 €

- Céspedes Navarro, Maria Virtudes. Grup d'Oncologia Ginecològica i peritoneal (GOGYP). 2021 SGR 00976. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Duration: 2022-2025. 36.000 €.
- Céspedes Navarro, Maria Virtudes. Contractes "Miguel Servet II" 2020. CPII20/00007. Instituto de Salud Carlos III (ISCIII). Duration: 2021-2024. 101.250,00 €
- Céspedes Navarro, Maria Virtudes. Validación de herramientas diagnósticas OMICS para la identificación de dianas terapéuticas y monitoreo de la recurrencia en glioblastoma. AC24/00157. Instituto de Salud Carlos III (ISCIII). Duration: 2025-2027. 199.467,00 €
- Edwards, Maria. InPHINIT 22. Fundació La Caixa. Duration: 2022-2025. 115.092,00 €

## DOCTORAL THESES DEFENDED

- Rovira Negre, Ramon. Metodología y herramientas para el aprendizaje de las habilidades quirúrgicas asociadas a la cirugía mínimamente invasiva. 20/11/2024. Universitat Autònoma de Barcelona. Supervisors: Llorba Olive, Elisa; Cassadó Garriga, Jordi. <https://hdl.handle.net/10803/693147>.

## SCIENTIFIC PRODUCTION

- Bebia V, Díaz B, Tejerizo A, Torne A, Benito V, Hernández A, Gorostidi M, Domingo S, Bradbury M, Luna R, Gil A, SPAIN G. Patterns of First Recurrence and Oncological Outcomes in Locally Advanced Cervical Cancer Patients: Does Surgical Staging Play a Role?. *Cancers*. 2024; 16(7):1423. DOI:10.3390/cancers16071423. PMID:38611101. IF:4,500 (Q1/3D). Document type: Article.
- Gavira J, Tapia JC, Romano A, Anguera G, Aguado M, Piedra A, Bosma F, Sánchez S, Martín C, Algaba F, Arce Y, Cajal TRY, Maroto P. Challenges of diagnosing homologous

- recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution. *Clinical & Translational Oncology*. 2024; 26(10). DOI:10.1007/s12094-024-03483-8. PMID:38722534. IF:2,800 (Q2/5D). Document type: Article.
- Pérez JA, Gálvez F, Guerra EM, Madariaga A, Manzano A, Martín C, Rubio MJ, Alarcón J, Barretina MP, Gaba L. SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023). *Clinical & Translational Oncology*. 2024; 26(11). DOI:10.1007/s12094-024-03531-3. PMID:39008159. IF:2,800 (Q2/5D). Document type: Article.
  - RAMON N, Mereu L, Planchamp F, Falconer H, El A, Barahona M, Fagotti A, Querleu D, Taskiran C. ESGE/ESGO/SERGS consensus statement on surgical steps in minimally invasive surgery in gynecologic oncology: transperitoneal and extraperitoneal approach for paraaortic lymphadenectomy. *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*. 2024; DOI:10.1136/ijgc-2024-005796. PMID:39317443. IF:4,100 (Q1/1D). Document type: Article.
  - Tapia JC, Bosma F, Gavira J, Sánchez S, Molina MA, Sanz J, Martín C, Anguera G, Maroto P. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021. *Clinical Genitourinary Cancer*. 2024; 22(3):102047. DOI:10.1016/j.clgc.2024.01.019. PMID:38430859. IF:2,300 (Q2/5D). Document type: Article.
  - Tapia JC, Gavira J, Anguera G, Sánchez S, Romano A, Bosma F, Molina A, Sanz J, Martín C, Algaba F, Maroto P. Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis. *Clinical & Translational Oncology*. 2024; 26(7). DOI:10.1007/s12094-024-03393-9. PMID:38421563. IF:2,800 (Q2/5D). Document type: Article.